New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities
New to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).
How this was made
The 30-second read
Why it matters
The article functions as visibility/positioning rather than a catalyst. Only one company-specific quantitative claim (MDCX 73% clearance rate) stands out, but the lack of trial context limits trading usefulness.
Market read
Mostly non-catalyst sponsored content; potential short-lived sentiment impact for MDCX due to a specific efficacy figure, but overall trading edge is low without new filings/data.
What to watch
The article does not clarify whether the cited Phase 2 73% clearance rate is newly released or previously known, nor does it provide trial size, comparator, or timeline—key for pricing risk.
Background
New to The Street is a sponsored business television brand; this item summarizes featured interviews across AI, healthcare, fintech, digital assets, and commodities.
Ticker impact
Lantern Pharma spotlights its proprietary AI platform Zeta for identifying drug candidates and predicting outcomes in rare cancers.
Low near-term impact; any move would likely be sentiment-driven rather than fundamentals.
The article is a sponsored broadcast description and does not introduce new trial results, approvals, or guidance.
Roadzen discusses AI use in auto insurance for risk assessment, accident prevention, and faster claims processing.
Minimal price impact expected.
No new measurable business development or earnings/operational figures are provided.
Health In Tech highlights its AI-enabled health insurance underwriting/administration platform and mentions financing and expansion.
Low impact; watch for follow-on disclosures elsewhere.
The article is descriptive and does not contain fresh, decision-grade details.
DataVault AI discusses secure data monetization and enterprise data management opportunities.
Negligible immediate impact.
No concrete transaction, contract, or performance metric is reported.
Medicus Pharma cites encouraging Phase 2 results with a 73% clinical clearance rate for basal cell carcinoma.
Mild positive bias possible, but magnitude uncertain without context (trial size, endpoints, timing).
A specific efficacy figure is provided, but the article does not state whether it is newly released or the full clinical context.
IGC Pharma discusses efforts to develop therapies to reduce agitation in Alzheimer’s disease for patients and caregivers.
Negligible immediate impact.
No new efficacy/safety data or milestone timing is included.
Gold Royalty explains its gold-linked royalty model via a diversified portfolio of 250+ royalties/streams.
Low impact; any reaction would depend on gold price moves rather than this article.
The piece is a broadcast overview and does not announce new royalty acquisitions or updated forecasts.
Market effects
Highlights ongoing investor interest in AI-enabled healthcare/fintech/insurtech and data monetization; however, provides no cross-company catalyst or regulatory trigger.
Primarily US-listed small/mid-cap attention via media exposure; no region-specific macro event cited.
Mentions broadcast reach across MENA/Latin America, but no global policy, commodity shock, or cross-border deal is described.
Counterpoint
Because this is sponsored programming, any trading response may fade quickly; the only actionable signal would come from separate, contemporaneous filings or press releases not included here.
Key entities
- companyLantern Pharma
Discusses AI platform Zeta for drug candidate identification and outcome prediction.
- companyRoadzen Inc.
Discusses AI-driven auto insurance risk assessment and claims processing.
- companyHealth In Tech
Discusses AI-enabled underwriting/administration and expansion plus financing.
- companyDataVault AI Inc.
Discusses secure data monetization and enterprise data management.
- companyMedicus Pharma
Cites Phase 2 clinical clearance rate for basal cell carcinoma using micro-needle delivery.
